Perimeter Medical Imaging AI (TSX-V:PINK, OTC:PYNKF) said it has initiated an additional clinical trial site at the Fred Hutch Cancer Center at the University of Washington in Seattle as part of an ongoing multi-center, randomized two-arm pivotal clinical trial.
The company noted the trial is evaluating the investigational Perimeter B-Series OCT combined with its proprietary ImgAssist AI (artificial intelligence) software when used during breast conservation surgeries.
"We are focused on expediting the development of our next-gen AI technology and its clinical evaluation in an ongoing pivotal trial,” Perimeter CEO Adrian Mendes commented in a statement.
“Our hope is that the data generated from this study will support the commercialization of Perimeter B-Series, supporting our aim to transform cancer surgery by delivering technology that improves patient outcomes and reduces healthcare costs.”
The University of Washington/Fred Hutch Cancer Center’s Dr Meghan Flanagan added: “Recognizing the unmet need in the field of breast cancer margin visualization, we are pleased to become the most recent site to participate in this clinical study.
“Combining AI with high-resolution imaging has the potential to become a new standard of care during breast conservation surgery, by reducing the number of repeat surgeries and, ultimately, delivering better outcomes for patients,” Dr Flanagan added.
Perimeter Medical Imaging AI is a medical technology company driven to transform cancer surgery with ultra-high-resolution, real-time, advanced imaging tools to address areas of high unmet medical need.
Contact the author at stephen.gunnion@proactiveinvestors.com